Changing stroke rehab and research worldwide now.Time is Brain! trillions and trillions of neurons that DIE each day because there are NO effective hyperacute therapies besides tPA(only 12% effective). I have 523 posts on hyperacute therapy, enough for researchers to spend decades proving them out. These are my personal ideas and blog on stroke rehabilitation and stroke research. Do not attempt any of these without checking with your medical provider. Unless you join me in agitating, when you need these therapies they won't be there.

What this blog is for:

My blog is not to help survivors recover, it is to have the 10 million yearly stroke survivors light fires underneath their doctors, stroke hospitals and stroke researchers to get stroke solved. 100% recovery. The stroke medical world is completely failing at that goal, they don't even have it as a goal. Shortly after getting out of the hospital and getting NO information on the process or protocols of stroke rehabilitation and recovery I started searching on the internet and found that no other survivor received useful information. This is an attempt to cover all stroke rehabilitation information that should be readily available to survivors so they can talk with informed knowledge to their medical staff. It lays out what needs to be done to get stroke survivors closer to 100% recovery. It's quite disgusting that this information is not available from every stroke association and doctors group.

Wednesday, January 9, 2019

Lipid-lowering agents reduce risk for CV events, but not inflammation

Well shit, the whole problem is inflammation  grabbing cholesterol out of the bloodstream and packing it into plaque.  Cholesterol has never been the problem.  So these interventions have never been reducing the primary cause of the problem, just a tackling a secondary issue.  When will your doctors acknowledge this fact?

Lipid-lowering agents reduce risk for CV events, but not inflammation


CHICAGO – Agents that decrease LDL cholesterol levels also reduce the risk for major adverse CV events, though they do not limit inflammation that may lead to these events, according to findings presented at American Heart Association Scientific Sessions.
“Statins, PCSK9 inhibitors and ezetimibe have all been shown to reduce major adverse CV events, owing to [a] reduction in LDL cholesterol,” the researchers wrote. “There has been an increasing interest [in] targeting inflammation to reduce major adverse CV events in patients with known or increased risk [for] coronary artery disease.”
The aim of the current study was “to determine whether contemporary lipid-lowering therapy in the form of statins or PCSK9 inhibition is associated with a discernible reduction in inflammation as measured by the levels of high-reactivity C-reactive protein.”
Haris Riaz, MD, a fellow at the Cleveland Clinic, and colleagues searched the PubMed, Embase and CENTRAL databases to identify randomized controlled clinical trials that compared statins and PCSK9 inhibitors with placebo or active control groups. All trials selected by the researchers reported rates of major adverse CV events and high-reactivity CRP (as mg/L).
Thirteen randomized controlled trials, including nine with statins and four with PCSK9 inhibitors, were selected from an initial review of 1,362 records. Meta analyses did not reveal substantial differences in high-reactivity CRP levels with high-dose statins when compared with placebo or low-dose statins (standard mean difference, –0.016; 95% CI, –0.099 to 0.066), regardless of a considerable decrease in major adverse CV events across all stratified high-reactivity CRP levels (HR = 0.81; 95% CI, 0.72-0.91). There was also no difference observed in high-reactivity CRP levels with treatment among patients in the PCSK9 trials (standard mean difference, 0; 95% CI, –0.017 to 0.017) in spite of a decrease, again, in major adverse CV events (HR = 0.86; 95% CI, 0.81-0.92).
“LDL cholesterol-lowering therapies reduce relative risk of major adverse CV events across high-reactivity CRP strata,” the researchers wrote. “However, contemporary lipid-lowering therapies do not mitigate the inflammatory risk.” - by Julia Ernst, MS
Reference:
Riaz H, et al. Abstract Su1229/1229. Presented at: American Heart Association Scientific Sessions; Nov. 10-12, 2018; Chicago.
Disclosures: The researchers report no relevant financial disclosures.

No comments:

Post a Comment